Amarin Corp Plcuk (AMRN) Cash from Investing Activities (2010 - 2026)
Amarin Corp Plcuk (AMRN) reported Cash from Investing Activities of -$8.3 million for Q1 2026, down 168.78% year-over-year from $12.1 million in Q1 2025, and down 136.01% quarter-over-quarter from -$3.5 million in Q4 2025.
Amarin Corp Plcuk (AMRN) Cash from Investing Activities (2010 - 2026) Analysis & Trends
Amarin Corp Plcuk (AMRN) has 16 years of Cash from Investing Activities data on file, last reported at -$8.3 million in Q1 2026.
- Cash from Investing Activities for Q1 2026 came in at -$8.3 million, down 168.78% year-over-year; the trailing twelve-month figure through Mar 2026 was -$11.5 million (up 81.59% YoY), and the FY2025 annual result was $8.8 million, up 119.2% from the prior year.
- Cash from Investing Activities declined to -$8.3 million in Q1 2026 per AMRN's latest filing, from -$3.5 million in the prior quarter.
- Over five years, Cash from Investing Activities peaked at $99.0 million in Q1 2022 and troughed at -$71.0 million in Q4 2023.
- A 5-year average of $6.1 million and a median of $4.7 million in 2024 frame the typical range for Cash from Investing Activities.
- On a YoY basis, Cash from Investing Activities climbed as much as 246.45% in 2024 and fell as far as 283.8% in 2024.
- A 5-year view of Cash from Investing Activities shows it stood at -$27.8 million in 2022, then tumbled by 155.22% to -$71.0 million in 2023, then jumped by 67.83% to -$22.8 million in 2024, then soared by 84.61% to -$3.5 million in 2025, then plunged by 136.01% to -$8.3 million in 2026.
- Business Quant data shows AMRN's Cash from Investing Activities at -$8.3 million in Q1 2026, -$3.5 million in Q4 2025, and -$12.1 million in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Investing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Gsk | 93,699,046.73 Bn | 93,699,041.77 Bn | 7.76 Bn | -1.98 Bn |
| 2 | Eli Lilly | 1,012.06 Bn | 1,006.77 Bn | 16.22 Bn | -3.92 Bn |
| 3 | Johnson & Johnson | 560.67 Bn | 538.62 Bn | 15.96 Bn | -1.04 Bn |
| 4 | AbbVie | 402.20 Bn | 392.85 Bn | 10.78 Bn | -574.00 Mn |
| 5 | Merck | 298.59 Bn | 292.94 Bn | 12.09 Bn | -10.21 Bn |
| 6 | Amgen | 188.77 Bn | 176.74 Bn | 5.87 Bn | -716.00 Mn |
| 7 | Gilead Sciences | 160.22 Bn | 152.49 Bn | 5.52 Bn | 1.77 Bn |
| 8 | Pfizer | 148.19 Bn | 135.42 Bn | -1.21 Bn | 785.00 Mn |
| 9 | Bristol Myers Squibb | 116.72 Bn | 106.26 Bn | 8.07 Bn | -131.00 Mn |
| 10 | Amarin Corp Plcuk | 5.84 Bn | 5.66 Bn | 17.77 Mn | -8.30 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -8.30 Mn |
| Mar 31, 2026 | -8.30 Mn |
| Dec 31, 2025 | -3.52 Mn |
| Dec 31, 2025 | -3.52 Mn |
| Sep 30, 2025 | -12.13 Mn |
| Sep 30, 2025 | -12.13 Mn |
| Jun 30, 2025 | 12.41 Mn |
| Jun 30, 2025 | 12.41 Mn |
| Mar 31, 2025 | 12.06 Mn |
| Mar 31, 2025 | 12.06 Mn |
| Dec 31, 2024 | -22.84 Mn |
| Dec 31, 2024 | -22.84 Mn |
| Sep 30, 2024 | -56.55 Mn |
| Sep 30, 2024 | -56.55 Mn |
| Jun 30, 2024 | 4.70 Mn |
| Jun 30, 2024 | 4.70 Mn |
| Mar 31, 2024 | 28.72 Mn |
| Mar 31, 2024 | 28.72 Mn |
| Dec 31, 2023 | -71.00 Mn |
| Dec 31, 2023 | -71.00 Mn |